Halozyme Therapeutics, Inc. (HALO) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-17

Business type: Franchise

How it makes money

Halozyme earns revenue through upfront licensing fees, milestone payments, bulk enzyme sales, and commercial royalties from pharmaceutical partners.

Halozyme licenses its proprietary ENHANZE and Hypercon drug delivery technologies to major biopharmaceutical companies. These partners combine the enzyme technology with their own biologic drugs to enable subcutaneous injection instead of intravenous infusion.

Profitability is driven primarily by commercial royalties received from partner product sales across ten approved products, supplemented by bulk rHuPH20 sales and developmental milestones.

What protects it: the moat

Halozyme protects its market position through patented enzyme technologies and co-formulations that can extend the patent life of partner drugs.

Management asserts that its proprietary recombinant human hyaluronidase enzyme, rHuPH20, and acquired hyperconcentration technologies create a defensible technological moat. Furthermore, co-formulating partner drugs with ENHANZE can secure additional regulatory exclusivity, extending commercial protection beyond the original intravenous drug patent expiry.

However, the business remains dependent on partners successfully navigating regulatory approvals and maintaining compliance to sustain these revenue streams.

What could damage it

A failure to obtain or maintain regulatory approvals for partnered products would directly impair the commercial milestone and royalty revenues Halozyme depends upon.

If regulatory agencies such as the FDA refuse or delay approval of partner product candidates due to insufficient safety data, or if commercialized products face adverse events and subsequent recalls, partners may halt development or sales. Because Halozyme's earnings rely heavily on partner commercialization and royalties, any disruption in partner product approvals or sales directly reduces incoming royalty revenue.

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Other companies in Biotechnology